gabapentin: the legal and safety record

The 2004 plea: the origin of the psychiatric prescription

Gabapentin was approved in 1993 for one thing: add-on therapy for seizures. In May 2004, Warner-Lambert pleaded guilty to two violations of the Food, Drug and Cosmetic Act and paid more than $430 million — including a $240 million criminal fine — over what the government called a widespread, coordinated national campaign to promote the drug for unapproved uses: bipolar disorder, pain, migraine, attention deficit disorder and more [1]. Central to the case was the manipulation of the scientific literature — publishing what supported the campaign, sitting on what did not.

A decade later, the civil track added more: reporting documents roughly $325 million paid to insurers in 2014 after a jury verdict for Kaiser was upheld on appeal [2]. We cite those figures as reporting; the plea is the part with a court record.

What this does and does not mean today

Hold both halves. The origin of gabapentin’s psychiatric use is court-documented marketing fraud — and your prescriber writing it today is doing nothing illegal and possibly nothing unreasonable. Off-label prescribing is legal, common, and sometimes right. What the record changes is the burden of the question: for a drug whose psychiatric prescription volume was built by a guilty-plea campaign rather than by approval trials, “what evidence supports this for my condition?” is not a hostile question — it is the only question. Gabapentin has no psychiatric approval and therefore no psychiatric approval trial — it sits in the “no number, here’s why” section of our trial-length page for exactly that reason.

Scale is why this matters: 46.8 million US prescriptions and 11.5 million patients in 2024 [4] — the highest-volume drug in our library, and the most-reported drug in our FAERS pulls. The volume, the reports, and the label are all on our gabapentin page, caveats first.

What is not in the record

• No Class I recall. Twenty-five recall records, all Class II or III, for manufacturing and quality problems [3]. FDA’s most serious category has never been applied.
• No adjudicated injury verdicts on psychiatric use. The 2004 case was about marketing conduct and payer losses — not a finding that gabapentin harmed any particular patient. A page that lets you infer otherwise is overreaching, in either direction.

Common questions

What was the Neurontin settlement about?

In May 2004, Warner-Lambert — by then a Pfizer subsidiary — pleaded guilty to two violations of the Food, Drug and Cosmetic Act and paid more than $430 million over the off-label promotion of Neurontin (gabapentin). The government described a coordinated national campaign promoting the drug for bipolar disorder, migraine, ADD and other unapproved uses; gabapentin was approved only as add-on therapy for seizures.

Is it legal for my doctor to prescribe gabapentin for anxiety or mood?

Yes. Off-label prescribing is legal and common, and it is the marketing of off-label uses by manufacturers that was illegal. The practical question for you is not legality but evidence: what trials support gabapentin for your specific condition? For many psychiatric uses the honest answer is thinner than the prescription volume suggests.

Did Pfizer pay more after 2004?

Yes — media and court reporting document roughly $325 million more in 2014 to settle claims by insurers and other payers over Neurontin marketing, following a jury verdict for Kaiser that was upheld on appeal. We cite that as reporting on top of the court-documented 2004 plea.

Has gabapentin had serious recalls?

No Class I recall — FDA’s most serious category — appears in the openFDA enforcement database. Twenty-five records exist, all Class II or III, for manufacturing and quality issues rather than anything about the molecule.

Is gabapentin dangerous?

That is a different question from anything on this page, and the record here does not answer it. What is documented: a 2019 FDA warning about respiratory depression when gabapentinoids are combined with opioids or in patients with respiratory risk, and growing scheduling at the state level. Bring the combination question to your prescriber if it applies to you.

Sources

Last verified 2026-08-31. Corrections change this date.